Synopsis
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;SUBCUTANEOUS - 10,000IU/M...DOSAGE - INJECTABLE;SUBCUTANEOUS - 10,000IU/ML (10,000IU/ML)
USFDA APPLICATION NUMBER - 20287
DOSAGE - INJECTABLE;SUBCUTANEOUS - 10,000IU/4...DOSAGE - INJECTABLE;SUBCUTANEOUS - 10,000IU/4ML (2,500IU/ML)
USFDA APPLICATION NUMBER - 20287
DOSAGE - INJECTABLE;SUBCUTANEOUS - 12,500IU/0...DOSAGE - INJECTABLE;SUBCUTANEOUS - 12,500IU/0.5ML (25,000IU/ML)
USFDA APPLICATION NUMBER - 20287
DOSAGE - INJECTABLE;SUBCUTANEOUS - 15,000IU/0...DOSAGE - INJECTABLE;SUBCUTANEOUS - 15,000IU/0.6ML (25,000IU/ML)
USFDA APPLICATION NUMBER - 20287
DOSAGE - INJECTABLE;SUBCUTANEOUS - 18,000IU/0...DOSAGE - INJECTABLE;SUBCUTANEOUS - 18,000IU/0.72ML (25,000IU/ML)
USFDA APPLICATION NUMBER - 20287
DOSAGE - INJECTABLE;SUBCUTANEOUS - 2,500IU/0....DOSAGE - INJECTABLE;SUBCUTANEOUS - 2,500IU/0.2ML (12,500IU/ML)
USFDA APPLICATION NUMBER - 20287
DOSAGE - INJECTABLE;SUBCUTANEOUS - 5,000IU/0....DOSAGE - INJECTABLE;SUBCUTANEOUS - 5,000IU/0.2ML (25,000IU/ML)
USFDA APPLICATION NUMBER - 20287
DOSAGE - INJECTABLE;SUBCUTANEOUS - 7,500IU/0....DOSAGE - INJECTABLE;SUBCUTANEOUS - 7,500IU/0.3ML (25,000IU/ML)
USFDA APPLICATION NUMBER - 20287
DOSAGE - INJECTABLE;SUBCUTANEOUS - 95,000IU/3...DOSAGE - INJECTABLE;SUBCUTANEOUS - 95,000IU/3.8ML (25,000IU/ML)
USFDA APPLICATION NUMBER - 20287
Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Parenteral
Topical
Solubilizers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
97
PharmaCompass offers a list of Dalteparin sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Dalteparin sodium manufacturer or Dalteparin sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dalteparin sodium manufacturer or Dalteparin sodium supplier.
A Liquaemin Lock Flush manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Liquaemin Lock Flush, including repackagers and relabelers. The FDA regulates Liquaemin Lock Flush manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Liquaemin Lock Flush API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Liquaemin Lock Flush manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Liquaemin Lock Flush supplier is an individual or a company that provides Liquaemin Lock Flush active pharmaceutical ingredient (API) or Liquaemin Lock Flush finished formulations upon request. The Liquaemin Lock Flush suppliers may include Liquaemin Lock Flush API manufacturers, exporters, distributors and traders.
click here to find a list of Liquaemin Lock Flush suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Liquaemin Lock Flush DMF (Drug Master File) is a document detailing the whole manufacturing process of Liquaemin Lock Flush active pharmaceutical ingredient (API) in detail. Different forms of Liquaemin Lock Flush DMFs exist exist since differing nations have different regulations, such as Liquaemin Lock Flush USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Liquaemin Lock Flush DMF submitted to regulatory agencies in the US is known as a USDMF. Liquaemin Lock Flush USDMF includes data on Liquaemin Lock Flush's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Liquaemin Lock Flush USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Liquaemin Lock Flush suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Liquaemin Lock Flush Drug Master File in Japan (Liquaemin Lock Flush JDMF) empowers Liquaemin Lock Flush API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Liquaemin Lock Flush JDMF during the approval evaluation for pharmaceutical products. At the time of Liquaemin Lock Flush JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Liquaemin Lock Flush suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Liquaemin Lock Flush Drug Master File in Korea (Liquaemin Lock Flush KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Liquaemin Lock Flush. The MFDS reviews the Liquaemin Lock Flush KDMF as part of the drug registration process and uses the information provided in the Liquaemin Lock Flush KDMF to evaluate the safety and efficacy of the drug.
After submitting a Liquaemin Lock Flush KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Liquaemin Lock Flush API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Liquaemin Lock Flush suppliers with KDMF on PharmaCompass.
Liquaemin Lock Flush Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Liquaemin Lock Flush GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Liquaemin Lock Flush GMP manufacturer or Liquaemin Lock Flush GMP API supplier for your needs.
A Liquaemin Lock Flush CoA (Certificate of Analysis) is a formal document that attests to Liquaemin Lock Flush's compliance with Liquaemin Lock Flush specifications and serves as a tool for batch-level quality control.
Liquaemin Lock Flush CoA mostly includes findings from lab analyses of a specific batch. For each Liquaemin Lock Flush CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Liquaemin Lock Flush may be tested according to a variety of international standards, such as European Pharmacopoeia (Liquaemin Lock Flush EP), Liquaemin Lock Flush JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Liquaemin Lock Flush USP).
